About Us

Overview

Propagenix is an R&D-stage cell therapy company engaged in the development and commercialization of technology which initially originated from the laboratory of Dr. Richard Schlegel of Georgetown University. The company was founded in 2014 and is located in the I-270 corridor of Montgomery County, Maryland. The company is dedicated to continuing to develop Propagenix technology for a wide range of applications in basic and translational biomedical research. Our vision is to enable the creation of new and more effective drugs, personalized diagnostics and cell therapies that will enhance human healthcare. The team has created a culture that places high value and thrives on scientific excellence, innovation, open and honest communication, a collaborative attitude, and a fast-paced work environment.

Picture 1 Leadership

Brian A. Pollok

Brian A. Pollok, Ph.D.
Co-Founder, President and CEO

Read more...
Sharon S. Challberg

Sharon S. Challberg, Ph.D
Co-Founder and COO

Read more...
Chengkang Zhang

Chengkang Zhang, Ph.D.
Principal Scientist

Read more...

Picture 2 Scientific Advisor

Richard Schlegel

C. Richard Schlegel, M.D., Ph.D
Georgetown University 

Read more...
Steven T Boyce

Steven T. Boyce, Ph.D
University of Cincinnati

Read more...
Laura E Niklason

Laura E. Niklason, M.D., Ph.D.
Yale University

Read more...
Lori Sussel

Lori Sussel, Ph.D.
University of Colorado

Read more...
Scott H. Randell

Scott H. Randell, Ph.D.
University of North Carolina

Read more...
Beate Illek

Beate Illek, Ph.D.
CHORI

Read more...

Picture 3 News

Stemcell Technologies signs exclusive license with Propagenix to commercialize EpiXTM, an innovation empowering epithelial cell biology and cell therapy

Vancouver, BC (September 20, 2017) – STEMCELL Technologies has signed an exclusive license with Propagenix of Rockville, MD to commercialize its patented EpiXTM…read more

line g

Propagenix Inc. lands three research grants to advance cell therapy technology for type 1 diabetes and lung disease

Rockville, MD (June 21, 2017) – Propagenix Inc., a privately-held biotechnology company focused on developing proprietary cellular technologies to enable new approaches in regenerative medicine, has been awarded three research grants totaling $950,000 in direct costs. …read more

Picture 4 Contact Us

Propagenix Inc.

9605 Medical Center Drive Ste 325
Rockville MD 20850
Support@Propagenix.com
(240) 713-3300

Name:*
Your email:
Company Name:
Your Phone Number:
-
Subject:
Message: